Publication | Closed Access

Sustained Symptomatic, Functional, and Hemodynamic Benefit With the Selective Endothelin-A Receptor Antagonist, Sitaxsentan, in Patients With Pulmonary Arterial Hypertension

HypertensionPulmonary Arterial HypertensionPulmonary CirculationCardiovascular DiseaseAntihypertensive TherapyVascular PharmacologyPhysiologyHemodynamic BenefitPulmonary HypertensionVascular BiologyPublic HealthMedicinePulmonary Vascular DiseaseAnesthesiology